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Recurrent acute otitis media (RAOM) represents a frequent challenge for the primary care physician and a major source 
of consultation to  otolaryngologists. We recommend insertion of ventilation tubes when school performance or speech 
acquisition is compromised. Chemoprophylaxis with trimethoprim-sulfamethoxazole (TMP/SMX) is still a viable option 
in other cases, despite the potential development of drug resistance. Other medical treatments are available, including 
vaccination and steroids. Finally, we have used limited mastoidectomy in carefully selected cases where retention of 
infected secretions and lack of aeration are implicated. 
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Treatment of recurrent acute otitis media (RAOM) 
represents a true challenge for primary care physicians. 
Failure to eradicate RAOM with primary medical 
management represents a frequent indication for referral 
to an otolaryngologist. The magnitude of this problem 
varies from country to country, but the phenomenon 
of M O M  exists worldwide. 
DEFINITIONS 
Acute otitis media (AOM) is defined by most authors 
to be recurrent when complete control of middle ear 
infection fails despite correctly administered medical 
treatment, usually in the form of antimicrobial agents. 
Typically, three or more isolated episodes of AOM 
within a 6-month time period are required for the 
diagnosis of RAOM. This does not include episodes 
of AOM which are diagnosed within 2-3 weeks of 
documented acute infection, as these may be misdiag- 
nosed (see ‘Practical Management of Uncomplicated 
Otitis Media’). The usual history is recidivism ofAOM 
after adequate treatment and an asymptomatic period 
of 4-5 weeks. Examination between episodes reveals 
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clear tympanic membranes and normal tympanometric 
data. Referral to an otolaryngologist is undertaken in 
an attempt to find an explanation for such recurrences 
and to seek a different therapeutic regimen. 
PATHOPHYSIOLOGY 
The attending otolaryngologist must consider several 
issues related to M O M :  
0 potential predisposing factors; 
0 potential causes of poor response to medical treat- 
0 possible complications; 
0 different approaches to management. 
ment; 
Predisposing factors 
Most of these are well known and include: 
0 prematurity and low birth weight; 
0 onset of AOM at an early age; 
0 environmental factors, specifically regular attendance 
in a day-care facility (providing exposure to viral and 
bacterial pathogens) and smoking in the household; 
0 urban setting, in which increased prevalence of 
AOM may be secondary to airway irritation resulting 
from high sulfur dioxide levels in the atmosphere. 
A similar increase in prevalence may, however, be 
present in a rural setting if there is heavy use of 
pesticides [l]; 
0 excessive use of antimicrobials in patient care as 
well as in agriculture, fisheries, and animal husbandry 
I21. 
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Potential causes of poor response to medical treatment 
In addition to these factors the anatomy and histology 
of the middle ear cleft may contribute to the high rate 
of RAOM. The middle ear space is connected via the 
eustachian tube with the nasopharynx, and maintains 
atmospheric pressure through this communication. 
Infected material can accumulate in the eustachian 
tube, particularly when the metachronic beating of cilia 
intended to clear these secretions is impaired by viral or 
bacterial invasion. This can lead to negative pressure 
development in the middle ear cleft and aspiration of 
eustachian tube secretions into the middle ear. This 
accumulation of infected secretions can occur not only 
in the mesotympanum (that portion of the middle ear 
which is visible through the tympanic membrane) but 
also in the epitympanum, or attic, where the upper 
parts of the incus and malleus are located. A loose 
fibrous diaphragm can be established separating disease 
in the non-visible epitympanum from the visible meso- 
tympanum. In addition, the epitympanum commu- 
nicates with the mastoid air cell system via a narrow 
channel, or aditus, which is the only ventilation for the 
mastoid. When the aditus is blocked by edema or 
infection, the mastoid air cells are isolated from 
the middle ear cleft and can likewise develop sub- 
atmospheric pressure. These isolated spaces, or ‘bottle- 
neck spaces’, act as a significant locus for retention of 
infected secretions and reinfection [ 3 ] .  
Thus, the basic mechanisms for middle ear con- 
tamination with nasopharyngeal secretions are in place; 
retention of these secretions can result in frequent re- 
infections until eradicated by antibiotherapy or establish- 
ment of normal pressure. Whereas in normal children 
nasopharyngeal flora may not reflect the bacterial 
composition of the middle ear, this correlation may be 
stronger in patients with M O M  [4]. 
Buildup of transitory or permanent middle ear 
effusion (MEE) is the consequence of repeated infect- 
ions within the middle ear complex, as demonstrated 
in another paper in this issue (M. Franqois). It may 
be viewed as a consequence of multiple insults to the 
middle ear mucosa. The distinction between RAOM 
and MEE is at times imprecise, and we believe that 
residual MEE, even if undetectable on otoscopy or tym- 
panometry, represents a significant cause for M O M .  
Complications of untreated RAOM 
When untreated, M O M  may lead to serious com- 
plications such as: 
0 adhesive otitis where all middle ear structures are 
frozen in non-aerated spaces; 
0 necrosis of ossicular structures, particularly the incus, 
with consequent permanent conductive hearing loss; 
0 tympanic membrane retraction pockets can evolve 
into the dangerous cholesteatoma, a prelude to 
chronic otitis media and a potential for erosion of the 
bony walls of the middle ear with possible sequelae 
of labyrinthitis, fistula, or brain infection. 
Practical management of RAOM 
This represents the major focus of this chapter. 
0 how to eradicate the present pathology? 
0 how to prevent further episodes? 
0 what therapeutic strategies should be considered after 
failure of primary management? 
The management goals in M O M  are multiple: 
The immediate approach 
This refers to the initial treatment of a child who 
has had 3+n  episodes of AOM in the previous 6 
months. The potential consequences of the disease 
need to be considered when devising a course of 
treatment. 
Children who have RAOM along with the follow- 
ing criteria should, in our opinion, undergo prompt 
surgical action to re-establish hearing [4]: presence of 
MEE demonstrated on otoscopy or suspected based on 
retracted tympanic membrane, type ‘B’ tympanogram, 
or cloudy mastoid on X-ray plus conductive hear- 
ing loss, possibly with speech delay or poor school 
performance. This policy is the subject of some contro- 
versy in the medical literature; we feel that it is logical 
(despite its deliberate ignoring of pathogenicity) as the 
result is a restored hearing capacity. The alternative, 
normally consisting of amplification with hearing aids, 
has disadvantages in terms of cost and, possibly, embar- 
rassment for the school-age child. 
Therefore, insertion of uni- or bilateral ventilating 
tubes should be considered in the patient population 
described above. There are few medical contraindica- 
tions for the necessary brief anesthetic. A myringotomy 
is performed, middle ear fluid is aspirated, and pressure 
equality between the middle ear cleft and atmosphere 
is maintained via a small plastic ‘grommet’ which 
remains in place for at least 6 months. We feel that 
the advantages inherent in placing the child’s aural 
development as the first priority outweigh the potential 
disadvantage of increased surgical intervention, despite 
recent opinion to the contrary [5]. This approach 
does not preclude the use of related medical treatments 
The treatment of the child with M O M  with 
normal speech and language, and without school 
problems, presents different options. Most episodes of 
M O M  occur during the cold weather months, along 
with a secondary peak, at least in Canada, during spring 
(April-June). The approaches used in this condition 
PI. 
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differ from country to country, often based on medical 
economic issues [7]. 
The simplest approach is to treat each episode of 
M O M  with standard antimicrobial therapy. However, 
several other therapeutic regimens have been proposed 
based on pathophysiological theories: 
0 use of corticosteroids (usually prednisone) with the 
belief that it stabilizes membrane phospholipid break- 
down and thus prevents formation of arachidonic 
acid, a significant cause of mucous production. 
0 non-steroidal anti-inflammatory drugs (NSAIDS), 
typically ibuprofen in North America, in order to 
inhibit cyclo-oxygenase, the enzyme which converts 
arachidonic acid to cyclic endoperoxidases which are 
direct precursors to prostaglandins (shown to be 
increased in experimental purulent MEE). 
Different dosages and durations of treatment for 
these medical interventions have been studied. A 
cost-effective treatment option may include cortico- 
steroids plus antimicrobials for M O M ,  with repeat 
antimicrobial therapy and eventual ventilation tube 
insertion reserved for non-responders. This approach 
has cost-benefit advantages in the USA [8] but has not 
been widely accepted in Canada. 
Antibacterials can be used either on a pro re 
necessita basis (usual approach) or via the more 
controversial use of prophylaxis. The use of antibiotic 
prophylaxis corresponds to a similar medical practice for 
the prevention of recurrent urinary tract infections in 
women [9]. 
A report from the Mayo Clinic demonstrated 
satisfactory results in this population using sulfonamides 
[I 01. Multiple trials of antimicrobial prophylaxis using 
either sulfonamides or ampicillin have confirmed this 
finding [ l l ] .  The potential development of drug- 
resistant bacterial strains has yet to be conclusively 
documented [12]. 
We personally compared the use of antimicrobial 
prophylaxis to the insertion of ventilation tubes in 
M O M  [13]; 125 subjects meeting strict entrance 
criteria were randomly assigned to treatment with 
either ventilation tube insertion or low-dose sulf- 
isoxazole (75 mg/kg/day) for 6 months. The study was 
conducted during alternating cold and warm seasons to 
remove any possible bias in this regard. We demon- 
strated that 33% of patients using antimicrobial prophy- 
laxis were effusion- and otitis-free at 18 months; we 
concluded that medical therapy should be attempted 
before surgical management in this patient population. 
Of interest was the finding of no statistically significant 
difference in terms of hearing level between the two 
groups at 6 months. We conducted a second study (in 
press) in which we used trimethoprim-sulfameth- 
oxazole (TMP/SMX) at a dose of 3 mg/kg TMP and 
15 mg/kg SMX daily for 3 months in 1257 patients; 
again, 34% were cured at 17 months with the 
remainder being genuine candidates for ventilation 
tube insertion. 
We are aware that this approach may increase the 
prevalence of resistant pathogens, particularly Strepto- 
coccus pneumoniae serotypes 23F and 19F which are 
reported to be resistant to TMPISMX [14]. In spite of 
concerns raised in other countries, notably the USA 
and Spain, our own preliminary data do not reveal 
significant TMP/SMX resistance among Streptococcus 
pneumoniae in our community. 
Other antimicrobials have been used in studies of 
chemoprophylaxis; amoxicillin has been the most com- 
mon [15], but erythromycin-sulfisoxazole, cefaclor, 
and amoxicillin-clavulanic acid have also been evaluated. 
We have found good compliance with the single daily 
dose of TMP-SMX. The new macrolides may have this 
same advantage, and clarithromycin has been used in 
this patient population by some physicians. Azithro- 
mycin, another macrolide, is currently available for 
pediatric use in Canada. Cefuroxime has also been 
proposed, but compliance seems to be poor secondary 
to its unpleasant taste. The same concerns raised 
regarding possible induction of drug resistance with 
TMP-SMX would apply to any choice of antimicrobial 
chemoprophylaxis. 
There has been no convincing evidence to support 
the use of alternative treatments. Decongestants and 
antihistamines are known to be ineffective, and may 
aggravate the problem by increasing the viscosity of the 
eustachian tube mucous blanket and further compro- 
mising the function of cilia. Adenoidectomy has been 
the subject of much controversy, but at present in our 
minds this has not been demonstrated to be of signi- 
ficant benefit. 
IS IT POSSIBLE TO PREVENT RAOM? 
0 Control of one of the most common causes of 
M O M ,  namely attendance in day-care facilities, is 
almost impossible in our present social system. 
0 Immunization to common pathogens is certainly a 
viable option: yearly vaccination against common 
viruses may to some extent help prevent M O M .  
Routine infant vaccination has been proposed [16]. 
Immunization against Streptococcus pneumoniae is pre- 
sently under investigation. 
0 The present concern regarding penicillin-resistant 
Streptococcus pneumoniae could be alleviated by the 
new agents which activate the action of T-lyrnpho- 
cytes [17]. Their efficacy and patient tolerance needs 
to be established. 
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0 Intravenous immunoglobulin therapy may be con- 
sidered in children with immunoglobulin deficien- 
cies, but this approach has significant disadvantages 
[181. 
A MINORITY OF PATIENTS (APPROXIMATELY 2%). 
CONTINUE TO DEVELOP INFECTIONS DESPITE 
OPTIMAL TREATMENT 
In this case the physician is typically presented with a 
patient who has received multiple courses of anti- 
biotics, who had ventilation tubes inserted, and who 
continues to experience episodes of otitis media with 
otorrhea. Fortunately, the majority of these episodes 
are related to external contamination (‘swimmer’s ear’), 
and the pathogens, typically Pseudomonar or Entero- 
bacter, can be effectively controlled using topical agents 
such as the aminoglycosides or fluoroquinolones. 
When anaerobes are a problem systemic clindamycin, 
amoxicillin-clavulanic acid, or imepenem may be 
necessary to control the infection. 
There is still a small subset of patients who have 
recurrent infections due to chronic subclinical in- 
fections of the mastoid complex due to disease trapped 
in the above mentioned ‘bottleneck spaces’. In our 
practice, a very conservative mastoidectomy, eradicat- 
ing all trapped disease, has proven very beneficial. 
In summary, M O M  remains a daily presentation 
to both primary care physicians and otolaryngologists. 
Careful and compliant administration of antimicrobials 
for acute infections may limit the extent of the disease 
[19]. At present, we still support an approach advoca- 
ting ventilation tubes for patients with compromised 
aural development, and a trial of antimicrobial 
prophylaxis for other children, with ventilation tubes 
reserved for failures. Vaccination against common 
middle ear pathogens may represent a hope for the 
future. 
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